Innovent Biologics, Inc.
Innovent Biologics, Inc. (HKSE: 1801) is trading at HK$99.70, about ₹1,221 at today's HKD/INR rate, as of 25 Sep 2026, 4:08 AM ET, down 0.10% today. Indian residents can buy Innovent Biologics from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$97.85
Today's high
HK$100.00
52 week low
HK$69.55
52 week high
HK$112.70
1801 opened at HK$98.00, closed previously at HK$99.80, and has traded between HK$69.55 and HK$112.70 over the past 52 weeks.
About
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
Key statistics
Avg. volume
14.25M
Market cap
HK$173.57B
P/E Ratio
120.57
Price-to-sales ratio
9.53
Enterprise value
CN¥133.54B
Free cash flow yield
6.35%
Debt-to-equity ratio
0.11
Return on equity
6.06%
ROIC
4.53%
Beta
0.24
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥13.04B
Earnings per share
CN¥0.48
Free cash flow
CN¥9.32B
Net profit margin
7.80%
Gross margin
80.96%
EBITDA
CN¥1.31B
Revenue growth
38.42%
Similar securities
This is not an investment recommendation
How to buy Innovent Biologics from India
Indian residents can buy Innovent Biologics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Innovent Biologics and place an order
Find Innovent Biologics by name or by its ticker, 1801, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Innovent Biologics trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Innovent Biologics position in HKD and INR. Innovent Biologics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Innovent Biologics from India
Trading and taxes when buying Innovent Biologics from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneInnovent Biologics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Innovent Biologics stock?
Yes. Innovent Biologics (1801) has been listed on the Hong Kong Stock Exchange since 2018, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Innovent Biologics share cost in rupees?
One Innovent Biologics share is HK$99.70 — about ₹1,221 at an HKD/INR rate of 12.25 on 24 Sep 2026. Both the Innovent Biologics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Innovent Biologics from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Innovent Biologics?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Innovent Biologics shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Innovent Biologics price. Paasa issues a capital-gains statement for your return.
Does Innovent Biologics pay a dividend?
No. Innovent Biologics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Innovent Biologics from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Innovent Biologics a Hong Kong SAR China company, and does that change how it is taxed?
Innovent Biologics trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Innovent Biologics trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Innovent Biologics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Innovent Biologics holding, its cost and its closing value.
How do I sell Innovent Biologics and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.